Evidence of Haloperidol Absorption After Topical Administration

• Status: Withdrawn
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This will be a blinded study to compare the absorption of topical haloperidol with placebo

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eric E. Prommer
• Treatments: Haloperidol; Haloperidol decanoate

Criteria

Inclusion Criteria

• Age: patient must be 18 years or older and less than 70 years of age.

• Provision of informed consent

• No previous adverse reaction to haloperidol

• No current use of haloperidol

• Good health

• No alcohol within 24 hours of the study

• No significant cardiovascular, gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease.

• Normal neurologic exam

Exclusionary Criteria

• Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study

• Recent cerebral trauma

• Study will exclude women who are pregnant and/or nursing

• Women who are of child bearing potential must have a negative urine pregnancy test.

• History of seizures

• Taking medications that can interact with haloperidol

• Subjects with significant cardiovascular (cardiac conduction deficits), gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease.